Short Interest in GlobeStar Therapeutics Co. (OTCMKTS:GSTC) Declines By 90.6%

GlobeStar Therapeutics Co. (OTCMKTS:GSTC) was the recipient of a large decline in short interest in March. As of March 31st, there was short interest totalling 3,100 shares, a decline of 90.6% from the March 15th total of 33,100 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 2,003,300 shares, the short-interest ratio is currently 0.0 days.

GlobeStar Therapeutics Trading Up 50.0 %

Shares of GSTC stock traded up $0.00 during trading hours on Monday, hitting $0.00. 8,815,019 shares of the company’s stock traded hands, compared to its average volume of 3,169,651. GlobeStar Therapeutics has a 12-month low of $0.00 and a 12-month high of $0.00.

About GlobeStar Therapeutics

GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. It offers Amethyst, a compound intended to treat neurodegeneration. The company was formerly known as AngioSoma, Inc and changed its name to GlobeStar Therapeutics Corporation in July 2021.